03 Feb 2022 Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin Investors | Therapeutics
18 Jan 2022 Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Investors | Therapeutics
10 Jan 2022 Update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant Diagnostics | Investors
22 Dec 2021 AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing Diagnostics | Investors
15 Dec 2021 AffiDX® SARS-CoV-2 antigen lateral flow test detects the Omicron variant Diagnostics | Investors
29 Nov 2021 Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000 Investors | Therapeutics
03 Nov 2021 Interview with Fiona McLaughlin – Avacta Chief Scientific Officer, Therapeutics Blogs | Therapeutics
02 Nov 2021 Update on UK Availability of AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test following Implementation of CTDA Regulations Diagnostics | Investors